Persistent cytomegalovirus infection: Association with profound immunodeficiency and treatment with interferon

Savita G Pahwa, Dahlia Kirkpatrick, Clara Ching, Carlos Lopez, Rajendra Pahwa, Elizabeth Smithwick, Richard O'Reilly, Charles August, Patrick Pasquariello, Robert A. Good

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) was repeatedly isolated from urine and saliva of a 20-month-old male child with recurrent episodes of pneumonia, high fever, rash, lymphadenopathy, oral ulceration, and neutropenia. Immunologic evaluation revealed decreased serum IgG and IgA, increased IgM, depressed T- and B-lymphocyte functions, and decreased natural killer (NK) activity for herpes simplex-type I virus-infected targets. NK activity was augmented following exposure of the patient's lymphocytes to interferon (IF) in vitro. The child was treated with interferon (four courses, dosage varying from 2 million U/day to 1 million U three times/week for periods of 10, 28, 80, and 67 days, respectively, interspersed over 9 months) and hyperimmune plasma infusions every 3 weeks. Toward the end of interferon therapy oral Levamisole was started and a feeding gastrostomy was inserted to provide nutritional support. Clinical recovery was associated with reversal of immunologic abnormalities except for the hypogammaglobulinemia. Aggressive antiviral therapy (e.g., with IF) followed by immunostimulation (e.g., with Levamisole) may prove effective in controlling certain viral infections in immunodeficiency disorders.

Original languageEnglish
Pages (from-to)77-89
Number of pages13
JournalClinical Immunology and Immunopathology
Volume28
Issue number1
DOIs
StatePublished - Jan 1 1983
Externally publishedYes

Fingerprint

Cytomegalovirus Infections
Interferons
Levamisole
Agammaglobulinemia
Gastrostomy
Nutritional Support
Virus Diseases
Simplexvirus
Therapeutics
Exanthema
Neutropenia
Cytomegalovirus
Saliva
Immunoglobulin A
Antiviral Agents
Immunoglobulin M
Immunization
Pneumonia
B-Lymphocytes
Fever

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Persistent cytomegalovirus infection : Association with profound immunodeficiency and treatment with interferon. / Pahwa, Savita G; Kirkpatrick, Dahlia; Ching, Clara; Lopez, Carlos; Pahwa, Rajendra; Smithwick, Elizabeth; O'Reilly, Richard; August, Charles; Pasquariello, Patrick; Good, Robert A.

In: Clinical Immunology and Immunopathology, Vol. 28, No. 1, 01.01.1983, p. 77-89.

Research output: Contribution to journalArticle

Pahwa, SG, Kirkpatrick, D, Ching, C, Lopez, C, Pahwa, R, Smithwick, E, O'Reilly, R, August, C, Pasquariello, P & Good, RA 1983, 'Persistent cytomegalovirus infection: Association with profound immunodeficiency and treatment with interferon', Clinical Immunology and Immunopathology, vol. 28, no. 1, pp. 77-89. https://doi.org/10.1016/0090-1229(83)90190-3
Pahwa, Savita G ; Kirkpatrick, Dahlia ; Ching, Clara ; Lopez, Carlos ; Pahwa, Rajendra ; Smithwick, Elizabeth ; O'Reilly, Richard ; August, Charles ; Pasquariello, Patrick ; Good, Robert A. / Persistent cytomegalovirus infection : Association with profound immunodeficiency and treatment with interferon. In: Clinical Immunology and Immunopathology. 1983 ; Vol. 28, No. 1. pp. 77-89.
@article{5e8f1c6c42ce4c7fb3a6c4b9bff3ba6d,
title = "Persistent cytomegalovirus infection: Association with profound immunodeficiency and treatment with interferon",
abstract = "Cytomegalovirus (CMV) was repeatedly isolated from urine and saliva of a 20-month-old male child with recurrent episodes of pneumonia, high fever, rash, lymphadenopathy, oral ulceration, and neutropenia. Immunologic evaluation revealed decreased serum IgG and IgA, increased IgM, depressed T- and B-lymphocyte functions, and decreased natural killer (NK) activity for herpes simplex-type I virus-infected targets. NK activity was augmented following exposure of the patient's lymphocytes to interferon (IF) in vitro. The child was treated with interferon (four courses, dosage varying from 2 million U/day to 1 million U three times/week for periods of 10, 28, 80, and 67 days, respectively, interspersed over 9 months) and hyperimmune plasma infusions every 3 weeks. Toward the end of interferon therapy oral Levamisole was started and a feeding gastrostomy was inserted to provide nutritional support. Clinical recovery was associated with reversal of immunologic abnormalities except for the hypogammaglobulinemia. Aggressive antiviral therapy (e.g., with IF) followed by immunostimulation (e.g., with Levamisole) may prove effective in controlling certain viral infections in immunodeficiency disorders.",
author = "Pahwa, {Savita G} and Dahlia Kirkpatrick and Clara Ching and Carlos Lopez and Rajendra Pahwa and Elizabeth Smithwick and Richard O'Reilly and Charles August and Patrick Pasquariello and Good, {Robert A.}",
year = "1983",
month = "1",
day = "1",
doi = "10.1016/0090-1229(83)90190-3",
language = "English",
volume = "28",
pages = "77--89",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Persistent cytomegalovirus infection

T2 - Association with profound immunodeficiency and treatment with interferon

AU - Pahwa, Savita G

AU - Kirkpatrick, Dahlia

AU - Ching, Clara

AU - Lopez, Carlos

AU - Pahwa, Rajendra

AU - Smithwick, Elizabeth

AU - O'Reilly, Richard

AU - August, Charles

AU - Pasquariello, Patrick

AU - Good, Robert A.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Cytomegalovirus (CMV) was repeatedly isolated from urine and saliva of a 20-month-old male child with recurrent episodes of pneumonia, high fever, rash, lymphadenopathy, oral ulceration, and neutropenia. Immunologic evaluation revealed decreased serum IgG and IgA, increased IgM, depressed T- and B-lymphocyte functions, and decreased natural killer (NK) activity for herpes simplex-type I virus-infected targets. NK activity was augmented following exposure of the patient's lymphocytes to interferon (IF) in vitro. The child was treated with interferon (four courses, dosage varying from 2 million U/day to 1 million U three times/week for periods of 10, 28, 80, and 67 days, respectively, interspersed over 9 months) and hyperimmune plasma infusions every 3 weeks. Toward the end of interferon therapy oral Levamisole was started and a feeding gastrostomy was inserted to provide nutritional support. Clinical recovery was associated with reversal of immunologic abnormalities except for the hypogammaglobulinemia. Aggressive antiviral therapy (e.g., with IF) followed by immunostimulation (e.g., with Levamisole) may prove effective in controlling certain viral infections in immunodeficiency disorders.

AB - Cytomegalovirus (CMV) was repeatedly isolated from urine and saliva of a 20-month-old male child with recurrent episodes of pneumonia, high fever, rash, lymphadenopathy, oral ulceration, and neutropenia. Immunologic evaluation revealed decreased serum IgG and IgA, increased IgM, depressed T- and B-lymphocyte functions, and decreased natural killer (NK) activity for herpes simplex-type I virus-infected targets. NK activity was augmented following exposure of the patient's lymphocytes to interferon (IF) in vitro. The child was treated with interferon (four courses, dosage varying from 2 million U/day to 1 million U three times/week for periods of 10, 28, 80, and 67 days, respectively, interspersed over 9 months) and hyperimmune plasma infusions every 3 weeks. Toward the end of interferon therapy oral Levamisole was started and a feeding gastrostomy was inserted to provide nutritional support. Clinical recovery was associated with reversal of immunologic abnormalities except for the hypogammaglobulinemia. Aggressive antiviral therapy (e.g., with IF) followed by immunostimulation (e.g., with Levamisole) may prove effective in controlling certain viral infections in immunodeficiency disorders.

UR - http://www.scopus.com/inward/record.url?scp=0020576619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020576619&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(83)90190-3

DO - 10.1016/0090-1229(83)90190-3

M3 - Article

C2 - 6307574

AN - SCOPUS:0020576619

VL - 28

SP - 77

EP - 89

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -